Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

Covid-19 HUF, 2021 NCT04346147

imatinib (n=55) vs. lopinavir/ritonavir plus chloroquine (n=-9)

randomized controlled trial   risk of bias NA

Studied treatment

-lopinavir/ ritonavir hydroxychloroquine-imatinib hydroxychloroquine-baricitinib hydroxychloroquine

Control treatment

no formal control groupcomparison between 3 active treatment groups

3 arms study

Patients

COVID-19 mild to moderate

Method

open-label

madrid, spain

prospective, phase II, randomized, open-label, 3 parallel groups study

Remark

no formal control groupcomparison between 3 active treatment groups